Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 4/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646375 | 0.93 | GRIN2B (0.55) | HTR2CHTR2AGRIN2BHPGDKMT2A | |
| Hydrochloric Acid SCHEMBL2224880 | 0.91 | HPGD (0.54) | HTR2CHTR2AGRIN2BHPGDKMT2A | |
| SCHEMBL9345993 | 0.89 | GRIN2B (0.56) | HTR2CHTR2AGRIN2BHPGDKMT2A | |
| SCHEMBL14876096 | 0.82 | GRIN2B (0.60) | GRIN2BALDH1A1FYNOPRM1OPRL1 | |
| SCHEMBL29447414 | 0.82 | GRIN2B (0.60) | GRIN2BALDH1A1FYNOPRM1OPRL1 | |
| SCHEMBL6620989 | 0.81 | GRIN2B (0.62) | HTR2CHTR2AGRIN2BHPGDKMT2A | |
| SCHEMBL11620522 | 0.81 | FYN (0.59) | GRIN2BALDH1A1FYN | |
| SCHEMBL11639039 | 0.76 | HTR2C (0.58) | HTR2CHTR2AGRIN2BHPGDKMT2A | |
| SCHEMBL7560367 | 0.74 | CHRNA7 (0.65) | HTR2CHTR2BTAAR1OPRM1OPRL1 | |
| SCHEMBL7563225 | 0.74 | CHRNA7 (0.65) | HTR2CHTR2BTAAR1OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | HTR2C 494/4885HTR2A 199/4885GRIN2B 101/4885 |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | HTR2C 475/4885HTR2A 193/4885GRIN2B 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.